anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Numerous observational studies have investigated on the correlation of whole, semi-skimmed, and skimmed milk with coronary artery disease (CAD) and myocardial infarction (MI) risk; However, no consensus has been reached and evidence on any causal links between these exposures and outcomes remains unclear. This study aimed to conduct univariate and multivariate Mendelian randomization (MR) analyses, using publicly released genome-wide association study summary statistics (GWAS) from the IEU GWAS database, to ascertain the causal association of milk with various fat content with CAD and MI risk.
METHODS: For the exposure data, 29, 15, and 30 single-nucleotide polymorphisms for whole milk, semi-skimmed milk, and skimmed milk, respectively, obtained from 360,806 Europeans, were used as instrumental variables. CAD and MI comprised 141,217 and 395,795 samples, respectively. We used inverse variance weighted (IVW), weighted median, MR-Egger regression, and MR Pleiotropy Residual Sum and Outlier analyses to determine whether pleiotropy and heterogeneity could skew the MR results. Sensitivity tests were conducted to verify the robustness of the results.
RESULTS: After adjusting for false discovery rates (FDR), we discovered proof that skimmed milk intake is a genetically predicted risk factor for CAD (odds ratio [OR] = 5.302; 95% confidence interval [CI] 2.261-12.432; P < 0.001; FDR-corrected P < 0.001) and MI (OR = 2.287; 95% CI 1.218-4.300; P = 0.010; FDR-corrected P = 0.009). Most sensitivity assessments yielded valid results. Multivariable MR for CAD and MI produced results consistent with those obtained using the IVW method. There was no causal relationship between whole or semi-skimmed milk, and CAD or MI.
CONCLUSION: Our findings indicate that the consumption of skimmed milk may increase the risk of CAD and MI. This evidence may help inform dietary recommendations for preventing cardiovascular disease. Further studies are required to elucidate the underlying mechanisms.
Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested). Probiotic: 10\^8 - 10\^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
Participants weighing less than (\<) 90 kilogram (kg) received two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once every 4 weeks (Q4W). Participants weighing greater than or equal to (\>=) 90 kg received two SC injections of 30 mg nemolizumab (60 mg total) at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
PURPOSE:To provide an agent for suppressing growth of AIDS virus by using glycyrrhizin which is an active component of licorice, as an active component. CONSTITUTION:Glycyrrhizin of formula or its salt is compounded with an excipient (e.g. potato starch, sodium alginate, etc.) and formed to the form of powder, granule, sugar-coated tablet, capsule, etc. It can be administered orally or parenterally at a dose of 200-400 mg daily for oral administration and 120-200 mg daily for parenteral administration for adult. An injection can be prepared by adding distilled water for injection, physiological saline water, detoxication aminoacetic acid, etc., to a solvent. The salt of glycyrrhizin is produced by reacting glycyrrhizin with an inorganic or organic base at equimolar ratio. Glycyrrhizin strongly suppresses the growth of AIDS virus HTLV-III/LAV, exhibits mutation-suppressing action to infected cell and is free from inhibition to reverse transcriptase which is common in conventional remedy for AIDS.
Following a novel immunotherapy process the archived aliquots of biologic material from each successive process is used to form a library in which further novel therapy can be developed. The patients essentially serve as the biologic assay for successful antigen processing response in the form of clinical response (i.e. tumor shrinkage, improvement in clinical status of disease). Only archived biologic material of clinically successful patients are then further used for further drug development. These patients are also evaluated for a positive MCH I or MHC II response. In the case of MHC II or antibody response: antibody producing cells (B-cells) are harvested or biopsied from various B-cell containing tissues and fused with multiple myeloma cells to form a further antibody production library, which may be further screened for antibodies to relevant antigens. In the case of MHC I or cell-mediated cytotoxic T or NK cell immune response, the archived electroporated immune cells can propagated and expanded in culture and transplanted back to the original patient or other patients in an allogeneic fashion.
The 5 year survival of oral cancer in Sweden is 55 % and only 3-4% in advanced cases, with poor quality of life. The etiology is hrHPV, exposure to tobacco and alcohol in 65% and poor dental status. All are lifestyle factors so there are many opportunities for prevention and intervention. In 2016, 352 individuals in Sweden died in oral cancer compared with 135 individuals who died of cervical cancer. Leukoplakia (LP), erythroplakia (EP) and oral lichen planus (OLP) are the dominating oral premalignant entities. The diagnosis are clinical and often by biopsies. There are two types of leukoplakia, homogeneous and non-homogeneous. The nonhomogeneous have a risk of malignant transformation of 3.6-8.9% in Scandinavia. OLP is a chronic inflammatory lesion where the atrophic and erosive types have a risk of cancer development of 0.5-2%. The potential for prevention is high, as the risk factors are well known. The Clinical examination discloses any potentially malignant lesions. Screening for cervical cancer using brush sampling is a well-established method but for the early detection of oral premalignant and malignant lesions, this is not yet an accepted standard procedure. However, there are studies that clearly show that brush sampling is a reliable and safe method to identify oral cancer and their potentially malignant precursor. In subjects with suspected pre-malignant tissue changes, measures should be taken to organize to establish a diagnosis. The brush sampling technique are shown to be a faster less costly, and for the patient less troublesome technique than traditional incisional biopsies but both methods require today, referral to specialist care. Dental hygienists and dentists can most probably be trained to perform brush biopsies of oral premalignant lesions, and when diagnosed, the patient can be referred to a specialist to have the lesion excised, and required controls can possibly be carried out in the primary care. Dental health professionals have a responsibility to perform routine intra- and extraoral examination on their patients for detecting abnormalities. As dental hygienists and dentists often see their patients on a regular basis, they have the opportunity to provide this screening, and at an early stage detect abnormalities. In Sweden, education and training in examination of the oral mucosa is a part of the curriculum in dental hygienist education, so there is an expectation that the dental hygienist routinely perform tactile and visual examinations in practice. However, dental hygienists are not allowed to diagnose an oral mucosal lesion, but are trained to identify abnormalities and determine whether the patient needs referral to a dentist. It is also to expect that the dental hygienist and dentist are capable to identify risk behaviors, and recommend, and offer smoking cessation or refer the patient to a certified profession for smoking cessation. Being aware of the increasing number of head, neck, and oral tumors we need to focus on establishing easy, fast and affordable methods for diagnosis, managed at the general dental health clinics, preferably by dental hygienists and dentists.
Cardiovascular Risk

  * Celecoxib may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. All nonsteroidal anti-inflammatory drugs (NSAIDs) may have a similar risk. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (5.1,14.6)
  * Celecoxib is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. (4, 5.1)



Gastrointestinal Risk

  * NSAIDs, including celecoxib, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (5.4)
PURPOSE: To obtain an org. product which contains amino acids in the form of oligopeptide refined by hydrolyzing whey protein, does not contain a protein of a specific mol.wt., ensures absorption and does not contain allergen. CONSTITUTION: Protein whey factions of soybean protein, etc., are prepd. as an aq. soln. and are subjected to prehydrolysis with pepsin preferably at pH2 to 3. These fractions are then subjected to enzymatically hydrolysis with tripsn- chymotrispsin and are ultrafiltered, concentrated and dried, by which the desired product contg. the amino acid as the ologipeptide form having 4 to 10 amino acids at a ratio of 40 to 60wt.% without contg. the protein of the mol.wt. of >=60000 is obtd.
PURPOSE:To obtain an aqueous solution of silk fibroin useful for cosmetic base, etc., excellent in storage stability, film-forming performances, etc., by blending an aqueous solution of silk fibroin with (meth)acrylic acid (derivative) with a radical polymerization catalyst and subjecting to graft polymerization. CONSTITUTION:(A) Sericin is removed from a silk fibroin raw material (e.g. raw silk waste or silk cloth waste) optionally in the presence of an activator in warm water or in the presence of an enzyme in warm water and the silk fibroin raw material is dried. (B) The silk raw material obtained in the process A is dissolved in a solvent (preferably aqueous solution of hydrochloride or nitrate of Ca or Mg) at 60-95 deg.C and then the salt is removed by using a dialyzer using a hollow yarn, etc. (C) The aqueous solution after the treatment is blended with one or more compounds (e.g. methacrylamide or methacrylic acid) selected from (meth)acrylic acid or a derivative thereof and stirred in the presence of a radical polymerization catalyst (e.g. persulfate or hydrogen peroxide) preferably in a nitrogen atmosphere under heating at 40-100 deg.C to produce an aqueous solution of silk fibroin modified with (meth)acrylic acid (derivative).
1. Technical Result Intensification of anti-inflammatory effect, prevention of side-effects and widening of assortment of medicinal pastes for filling tooth root. 2. Essence A medicinal paste for filling tooth root comprises hydro apatite (HA), zinc oxide, combined preparation of bacteriophage and eugenol. 3. Field of Application Medicine, stomatology.
The literature has shown the relevance of nutritional and metabolic aspects in patients with epilepsy. This study evaluated the relationship between clinical variables and plasma proteins and compared the variables between seizure frequency and neurological examination. A pilot study was carried out with eighty-four (n = 84) adults patients with epilepsy. The relationship between clinical variables of the disease (age at disease onset, neurological examination, current type and frequency of seizures, duration of disease, amount of antiseizure medications-ASM used and type and etiology of epilepsy) and plasma proteins (albumin and transferrin) was investigated. In the statistical analysis, the chi-square, Fisher, Mann-Whitney, Kruskal-Wallis tests, Spearman coefficient and univariate logistic regression were used. There was a significant association between the use of antiseizure medications (ASM) (p = 0.0105) and altered neurological examination (p = 0.0049), compared with the frequency of seizures, and between albumin and gender (p = 0.0005), and albumin and etiology of epilepsy (p = 0.0186). There was a significant low-intensity and inverse linear correlation (coefficient = -0.31363, p = 0.0037) between albumin and disease duration. In the logistic regression model, a significant association was only observed between the number of ASM and the frequency of seizures (p = 0.0120; OR = 3.368; 95% CI = 1.305-8.691). There was no association between plasma proteins and the outcomes of seizure frequency and neurological examination. The number of ASM and not protein metabolism was associated with frequency of seizures in patients with epilepsy.
Post-acute sequelae of COVID-19 (PASC) or the continuation of COVID-19 (Coronavirus disease 2019) symptoms past 12 weeks may affect as many as 30% of people recovering from a SARS-CoV-2 (severe acute respiratory coronavirus 2) infection. The mechanisms regulating the development of PASC are currently not known; however, hypotheses include virus reservoirs, pre-existing conditions, microblood clots, immune dysregulation, as well as poor antibody responses. Importantly, virus neutralizing antibodies are essential for COVID-19 recovery and protection from reinfection but there is currently limited information on these immune regulators and associated cytokines in PASC patients. Understanding the key drivers of general and specific symptoms associated with Long COVID and the presence of virus neutralizing antibodies in PASC will aid in the development of therapeutics, diagnostics, and vaccines which currently do not exist. We designed a cross-sectional study to investigate systemic antibody and cytokine responses during COVID-19 recovery and PASC. In total, 195 participants were recruited in one of four groups: (1) Those who never had COVID-19 (No COVID); (2) Those in acute COVID-19 recovery (Acute Recovery) (4-12 weeks post infection); (3) Those who recovered from COVID-19 (Recovered) (+ 12 weeks from infection); and (4) those who had PASC (PASC) (+ 12 weeks from infection). Participants completed a questionnaire on health history, sex, gender, demographics, experiences with COVID-19 acute and COVID-19 recovery/continuing symptoms. Serum samples collected were evaluated for antibody binding to viral proteins, virus neutralizing antibody titers, and serum cytokine levels using Ella SimplePlex Immunoassay™ panels. We found participants with PASC reported more pre-existing conditions (e.g. such as hypertension, asthma, and obesity), and PASC symptoms (e.g. fatigue, brain fog, headaches, and shortness of breath) following COVID-19 than COVID-19 Recovered individuals. Importantly, we found PASC individuals to have significantly decreased levels of neutralizing antibodies toward both SARS-CoV-2 and the Omicron BA.1 variant. Sex analysis indicated that female PASC study participants had sustained antibody levels as well as levels of the inflammatory cytokines GM-CSF and ANG-2 over time following COVID-19. Our study reports people experiencing PASC had lower levels of virus neutralizing antibodies; however, the results are limited by the collection time post-COVID-19 and post-vaccination. Moreover, we found females experiencing PASC had sustained levels of GM-CSF and ANG-2. With lower levels of virus neutralizing antibodies, this data suggests that PASC individuals not only have had a suboptimal antibody response during acute SARS-CoV-2 infection but may also have increased susceptibility to subsequent infections which may exacerbate or prolong current PASC illnesses. We also provide evidence suggesting GM-CSF and ANG-2 to play a role in the sex-bias of PASC. Taken together, our findings maybe important for understanding immune molecular drivers of PASC and PASC subgroups.
In one aspect, the invention relates to an immunogenic composition that includes a mutant  Clostridium difficile  toxin A and/or a mutant  Clostridium difficile  toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type  C .  difficile  toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
The goal of the current research is to conduct a randomized controlled trial of the ©Violence, Evidence, Guidance, and Action (VEGA), Family Violence Education Resources (VEGA Project, 2019) among a sample of clinical psychology graduate students across Canadian universities to assess whether it is effective in improving responses to child maltreatment and intimate partner violence (IPV) (collectively referred too throughout as "family violence") in clinical settings. For this study, students belonging to accredited Clinical Psychology doctoral programs from Canadian universities will be randomized into either (a) an intervention group that will complete the online VEGA Family Violence Education Resources, OR (b) a control group who will not complete the training (but who will have the opportunity to do so following the completion of outcome data collection ; wait-list control). Throughout this evaluation study, a variety of pre- and post-training outcome measures will be administered participants; these measures are intended to assess reactions to the training, changes in family violence knowledge, changes in attitudes toward IPV and child maltreatment, and clinically relevant behaviours in responding to suspicions and disclosures of family violence by clients/patients in clinical practice settings. After completing the measures and the training, a subset of randomly selected students from the intervention group will be invited to participate in a one-on-one qualitative interview with a member of the research team via Zoom, during which they will be asked to share their perspectives on the training and how it impacted/may impact their work (or not) with clients who have experienced IPV and/or child maltreatment. Information provided from the quantitative measures and qualitative interviews will allow us to answer the following questions: (1) Was the training engaging and relevant to clinical psychology students? (2) Was the training able to improve the knowledge and self-efficacy of students regarding family violence? (3) Was the training able to change behaviours and improve the response of clinical psychology students to clients (or future clients) experiencing family violence in their professional training settings? Note: Used with permission from © 2020 VEGA Project, McMaster University. All rights reserved. All questions regarding the use and evaluation of the VEGA Family Violence Education Resources, or the VEGA Project more generally, should be directed to Dr. Melissa Kimber at vega@mcmaster.ca
The optimal therapeutic management of cyclic vomiting syndrome (CVS) remains elusive. The objective of this study was to document our clinical experience in the Pediatric Department of San Marco Hospital and to survey the literature on pediatric CVS treatment, aiming to update the guidance on the most effective treatment strategies for this not-so-uncommon condition. Data from 70 patients with CVS, admitted to our Pediatric Department between September 2011 and December 2021, were aggregated and included in the study. A systematic review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool and the A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2) method. Treatment responses, as observed both in the literature and in our own experience, are variable. In our cohort, topiramate demonstrated superiority over other pharmacological treatments, exhibiting an efficacy of 85% in the patients treated. A universally accepted treatment protocol for pediatric CVS has yet to be established. The efficacy of first-line treatments is generally suboptimal, suggesting that topiramate might serve as a safe and effective primary therapeutic option for pediatric CVS.
Three tablets of matching placebo will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 1 placebo tablet in addition to their ongoing antidepressant.
To investigate the endothelialization of covered and bare stents deployed in the canine carotid arteries and subclavian arteries for treating experimental aneurysms and arteriovenous fistulas, twenty aneurysms were created in 10 dogs, and 20 fistulas in another 10 dogs. The Willis balloon-expandable covered stent and a self-expandable covered stent were used to treat these lesions, and a self-expandable bare stent was deployed in the subclavian artery for comparison. Followed up for up to 12 months, the gross observation, pathological staining, and scanning electronic microscopic data were analyzed. Two weeks after creation of animal model, thirty self-expandable covered stents and ten balloon-expandable covered stents were deployed. Fifteen bare stents were deployed within the left subclavian arteries. Twenty days after stenting, the aneurysm significantly shrank. At 6 months, the thrombi within the aneurysm cavity were organized. Three to 12 months later, most covered and bare stents were covered by a thin transparent or white layer of endothelial intima. Layers of intima or pseudomembrane were formed on the stent 20-40 days after stent deployment. Over three months, the pseudomembrane became organized, thinner, and merged into the vascular wall. Under scanning electronic microscopy, the surface of covered and bare stents had only deposition of collagen fibers and rare endothelial cells 20-40 days after stenting. From three to ten months, the endothelial cells on the internal surface of stent became mature, with spindle, stripe-like or quasi round morphology along the blood flow direction. Over time, the endothelial cells became mature. In conclusion, three months after deployment in canines' arteries, the self-expandable bare and covered stents have mostly been covered by endothelial cells which become maturer over time, whereas the balloon-expandable covered stents do not have complete coverage of endothelial cells at three months, especially for protruding stent struts and areas. Over time, the endothelialization will become mature.